In KEYNOTE-189, 616 patients with metastatic WT nonsquamous NSCLC and any level of PD-L1 expression were randomized, in a 2:1 ratio, to pembrolizumab at 200 mg IV or placebo every three weeks for up to two years, both combined with platinum-pemetrexed for four cycles. Here, CD274 is linked to non-small cell lung carcinoma.